Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)

Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
First published April 14, 2020,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 94 no. 15 Supplement 4558
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 14, 2020.
Copyright & Usage: 
© 2020

Author Disclosures

    1. Robert Fox1,
    2. Heinz Wiendl2,
    3. Nicola De Stefano3,
    4. Johann Sellner4 and
    5. Andreas Mühler
    6. for the EMPhASIS study team5
  1. Robert Fox1,
  2. Heinz Wiendl2,
  3. Nicola De Stefano3,
  4. Johann Sellner4 and
  5. Andreas Mühler
  1. 1Cleveland Clinic
  2. 2University of Muenster
  3. 3University of Siena
  4. 4Landesklinikum Mistelbach-Gänserndorf
  5. 5Immunic Therapeutics

Article usage

Article usage: April 2020 to February 2023

AbstractFullPdfSource
Apr 20201700Highwire
May 20203800Highwire
Jun 20202900Highwire
Jul 20201700Highwire
Aug 20201700Highwire
Sep 2020800Highwire
Oct 2020600Highwire
Nov 2020600Highwire
Dec 20201400Highwire
Jan 2021800Highwire
Feb 20211500Highwire
Mar 20211300Highwire
Apr 2021900Highwire
May 2021300Highwire
Jun 2021600Highwire
Jul 20211500Highwire
Aug 20211400Highwire
Sep 2021500Highwire
Oct 2021800Highwire
Nov 20211300Highwire
Dec 20211500Highwire
Jan 2022900Highwire
Feb 2022800Highwire
Mar 20222500Highwire
Apr 20221300Highwire
May 2022300Highwire
Jun 20221600Highwire
Jul 2022800Highwire
Aug 2022500Highwire
Sep 2022500Highwire
Oct 2022600Highwire
Nov 2022600Highwire
Dec 2022500Highwire
Jan 2023600Highwire
Feb 20231500Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me